Listen "Updates from December 2020"
Episode Synopsis
The 1st episode of 2021 covers 5 FDA updates from December 2020
-Pralsetinib for RET-mutated medullary thyroid cancer
-The new HER2-targeting margetuximab
-Selinexor and the Boston study
-Relugolix, an oral GnRH antagonist
-Adjuvant osimertinib approved (ADAURA)
-Pralsetinib for RET-mutated medullary thyroid cancer
-The new HER2-targeting margetuximab
-Selinexor and the Boston study
-Relugolix, an oral GnRH antagonist
-Adjuvant osimertinib approved (ADAURA)
More episodes of the podcast OncoPharm
Iberdomide
20/08/2026
Kidney Cancer in a Nutshell
13/08/2026
Small Cell Lung Cancer and CINV Updates
06/08/2026
Zidesamtinib & PPIs in Pacific
30/07/2026
Gedatolisib et al
23/07/2026
Endurance Part 2
16/07/2026
A Decade of CAR-T, Ocra-T, & POLARGO
09/07/2026
Breast Cancer Updates and T-Cell Stemness
25/06/2026
ASCO '26
11/06/2026
